Dyne Therapeutics, Inc. (DYN)

NASDAQ: DYN · Real-Time Price · USD
11.83
+0.10 (0.90%)
Apr 30, 2025, 4:00 PM EDT - Market closed
0.90%
Market Cap 1.34B
Revenue (ttm) n/a
Net Income (ttm) -317.42M
Shares Out 113.63M
EPS (ttm) -3.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,256,428
Open 11.28
Previous Close 11.72
Day's Range 11.28 - 11.94
52-Week Range 6.36 - 47.45
Beta 1.21
Analysts Strong Buy
Price Target 47.73 (+303.64%)
Earnings Date May 13, 2025

About DYN

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and i... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 17, 2020
Employees 191
Stock Exchange NASDAQ
Ticker Symbol DYN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price forecast is $47.73, which is an increase of 303.64% from the latest price.

Price Target
$47.73
(303.64% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned fo...

6 days ago - GlobeNewsWire

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

- Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM, ...

15 days ago - GlobeNewsWire

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with geneticall...

16 days ago - GlobeNewsWire

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with geneticall...

5 weeks ago - GlobeNewsWire

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -

5 weeks ago - GlobeNewsWire

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

- Continued favorable safety profile for DYNE-251 - - DELIVER Registrational Expansion Cohort is fully enrolled;  data from this cohort planned for late 2025 - - Potential for Biologics License Applic...

6 weeks ago - GlobeNewsWire

Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker

Positive biomarker and functional data released from phase 1/2 ACHIEVE study, using DYNE-101 to treat patients with Myotonic Dystrophy Type 1. Data from registration cohort phase 1/2 ACHIEVE study, us...

6 weeks ago - Seeking Alpha

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc., focused on developing therapies for genetically driven neuromuscular diseases.

7 weeks ago - Benzinga

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetical...

7 weeks ago - GlobeNewsWire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

- Received FDA Fast Track Designation for DYNE-101 in DM1 - - Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 Planned for Mid-2025 to Support Submission for U.S....

2 months ago - GlobeNewsWire

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

- Data from DELIVER and ACHIEVE Clinicals Trial to be Presented - - Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on the Use of Splicing Correction as a Prognostic Biomark...

2 months ago - GlobeNewsWire

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics f...

3 months ago - GlobeNewsWire

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

- Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 - WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.

3 months ago - GlobeNewsWire

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

On Friday, Dyne Therapeutics, Inc.  DYN revealed new data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).

3 months ago - Benzinga

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and robust ...

3 months ago - GlobeNewsWire

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics ...

3 months ago - GlobeNewsWire

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics ...

4 months ago - GlobeNewsWire

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Dyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 and DYNE-251 targeting DM1 and DMD, respectively. DYNE-251 shows significan...

6 months ago - Seeking Alpha

Dyne Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.  (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo...

6 months ago - GlobeNewsWire

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeut...

6 months ago - Accesswire

Dyne Therapeutics Inc Is Being Sued For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / October 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeut...

6 months ago - Accesswire

Dyne Therapeutics Inc May Have Committed Securities Fraud And Stockholders With Losses Are Urged To Reach Out To The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / October 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeut...

6 months ago - Accesswire

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeut...

6 months ago - Accesswire

Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeut...

6 months ago - Accesswire

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Related Infractions

LOS ANGELES, CA / ACCESSWIRE / October 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeut...

6 months ago - Accesswire